Research
JPMorgan Initiates Larimar Therapeutics at Overweight With $9 Price Target
Larimar Therapeutics (LRMR) has an average rating of buy and mean price target of $15.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$LRMR
